Tharimmune (THAR) Form 4: 5,000 options at $3.075 granted
Tharimmune, Inc. (THAR) reported insider activity on a Form 4.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tharimmune, Inc. (THAR) reported insider activity on a Form 4. Director James Liddy received a stock option grant for 5,000 derivative securities on 11/03/2025 at an exercise price of $3.075 per share. The options are exercisable on 11/03/2025 and expire on 11/03/2035, covering underlying Common Stock (5,000 shares). Following this transaction, Liddy beneficially owns 55,000 derivative securities. The ownership form is reported as Direct (D).
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 5,000 | $0.00 | $0.00 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did THAR director James Liddy report on Form 4?
What is the exercise price and date for the THAR options?
When do the reported THAR stock options expire?
How many derivative securities does James Liddy hold after the transaction?
What was the Form 4 transaction code for the THAR option grant?
What is the ownership form for the reported THAR securities?
AI-generated analysis. How Rhea-AI works. Not financial advice.